Search PubMed⌕ Search

Biomedical subjects

M P Dumont

Publications and source records attributed to M P Dumont.

16 recordsLinked to original sources
PubMed1992

Phase II preclinical drug screening in human tumor xenografts: a first European multicenter collaborative study.

In a European joint project carried out in 6 laboratories a disease-oriented program was set up consisting of a panel of 7 tumor types, each represented by 4 to 8 different human tumor lines, for secondary screening of promising anticancer drugs. Human tumor lines were selected on the basis of differences in histology, growth rate, and sensitivity to conventional cytostatic agents. Xenografts were grown s.c. in nude mice, and treatment was started when tumors reached a mean diameter of 6 mm in groups of mice where at least 6 tumors were evaluable. Drugs were given at the maximum tolerated dose. For evaluation of drug efficacy, median tumor growth curves were drawn, and specific growth delay and treated/control x 100% were calculated. Doxorubicin (8 mg/kg i.v. days 1 and 8) was effective (treated/control < 50%, and specific growth delay > 1.0) in 0 of 2 breast cancers, 1 of 3 colorectal cancers, 2 of 5 head and neck cancers, 3 of 6 non-small cell lung cancers, 4 of 6 small cell lung cancers, 0 of 3 melanomas, and 3 of 6 ovarian cancer lines. Amsacrine (8 mg/kg i.v. days 1 and 8) was not effective, while datelliptium (35 mg/kg i.p. days 1 and 8) was active against 2 of 6 small cell lung cancer lines. Brequinar sodium (50 mg/kg i.p. days 1-5) showed efficacy in 4 of 5 head and neck cancers, 5 of 8 non-small cell lung cancers, and 4 of 5 small cell lung cancer lines. The project has been shown to be a feasible approach. Clinical activity for doxorubicin and inactivity for amsacrine against solid tumor types was confirmed in the human tumor xenograft panel. Additional anticancer drugs will be studied in the European joint project to further define the reliability of this novel, promising screening approach.

Amsacrine↗
PubMed1989

Psychotoxicology: the return of the mad hatter.

Psychiatrists have not been attentive to the huge and expanding capacity of neurotoxic substances to induce symptoms of emotional and behavioral dysfunction. The psychiatric implications of exposure to heavy metals, volatile solvents, pesticides and behavioral teratogens is reviewed. Case histories reflect the risk of misdiagnosing psychotoxic episodes and the futility of standard interventions. The variability of behavioral responses to psychotoxic agents challenges a psychiatric nomenclature based on specific disease categories. Psychiatrists should routinely inquire about exposure to toxic substances. The issues raised will result in confrontation with social and economic forces usually ignored by clinicians.

Abnormalities, Drug-Induced↗